Department of Pharmaceutical Sciences And Drug Research

29/03/2024

Base Pharmaceuticals pvt Ltd

24/09/2019

probing into the reported N-nitrosodimethylamine in it at low levels
Reddy’s Laboratories Limited on said that it is of its as a precautionary measure, following the ongoing probe by the US Food and Drug Administration (USFDA) into the reported impurity N-nitrosodimethylamine in it at low levels.
Ranitidine is an Over-The-Counter (OTC) and which decreases the amount of acid created by the stomach. “Dr Reddy’s is still evaluating potential impact of the issue. As a precautionary measure, Dr Reddy’s is suspending all shipments worldwide of Ranitidine products until the investigation (by the FDA) outcome is available. We have both a prescription and an over-the-counter portfolio of the product,” Dr Reddy’s spokesperson told PTI in an email reply.
Article Continues Below

The FDA in a statement on September 13 had said it is working with international regulators and industry partners to determine the source of this impurity in Ranitidine and examining levels of NDMA in Ranitidine and evaluating any possible risk to patients.
Though the FDA is not calling for individuals to stop taking Ranitidine at this time, however, patients taking the prescription and wishing to discontinue its use should talk to their health care professionals about other treatment options, the US drug regulator said. “We expect to provide an update in the coming days. The FDA is not calling for individuals to stop taking Ranitidine at this time.
Consumers and health care professionals should report any adverse reactions with Ranitidine to the FDA’s MedWatch program to help the agency better understand the scope of the problem,” Dr Reddy’s said. The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines such as Valsartan since last year.
Aurobindo Pharma, Torrent Pharmaceuticals, Hetero Labs and many other multinationals have voluntarily recalled Valsartan from the USA market following the alleged cancer causing impurity-NDMA.

15/09/2019

: In a bid to rationalise , major is shutting two units at its Vadodara-based &D centre, terminating of around 85 . The scientists were engaged in the clinical unit, which is part of R&D operations.

Sources said the company’s R&D centre at Gurgaon (started by erstwhile Ranbaxy) will now undertake the clinical research handled by the Vadodara facility, while the rest of the research operations will continue at the Vadodara unit.

Over the years, drug companies — including Lupin and Piramal — have undertaken a rationalisation exercise to cut costs. They either reduced or shut their innovative and specialised research operations to protect margins in an industry that is showing signs of a slowdown.

In the last few months, the sector is facing stiff headwinds with margins of most drug companies under pressure, bogged down by price erosion in US businesses. The pharma retail market, after years of mid-teens growth, is feeling the heat with volumes slowing down over the past five months, and the market recording muted of under 7% in June, as against 10-12% in the past. The sector has been pulled down by multiple factors, including increase in use of low-cost , and lower sales in acute segment. The Sun Pharma closed 1% lower at Rs 421 on the BSE on Friday.

At present, Sun Pharma employs around 2,000 scientists across six major centres located at Vadodara, , Mumbai, Israel, Canada and the US. The company’s R&D spend as a percentage of sales reduced to 6.9% in FY19 from 8.6% in the previous fiscal.

Confirming the development, a Sun Pharma spokesperson said, “While we continue to make investments in our R&D operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, we are discontinuing operations at two centres at Tandalja and Akota, Vadodara. The bio-equivalence studies from these centres will be transferred to our other facilities. We are offering full support to the affected employees and helping them with outplacement services.”

Sources said the employees had no prior intimation about termination of their services and learnt about it when they reported for work on Friday. According to regulations, Three months’ salary will be given to those who lost jobs.

In 2016, Sun Pharma — run by billionaire Dilip Shanghvi — had executed several rounds of manpower restructuring when it acquired Gurgaon-based Ranbaxy for a “better utilisation of talent”. The pruning is learnt to have been done across several operations and levels, and involved hundreds of employees.
Dilip Shanghvi

15/09/2019

Baba Ramdev's Patanjali is in a Free-fall

Whatever Patanjali is going through is self-inflicted. Its slowdown is not related to the slowdown in the economy but to the illogical expansion, ill-maintained supply chain and poor product quality.

The company invested hugely in advertisements that made customers excited to try the products. With customer’s demand, channel partners also got excited. But the company started sourcing products without quality control. Now the consumer is turned off with their products and recurring shortages. It is very difficult for Patanjali to make a comeback.

Not just sales, the brand equity is also being damaged, experts claim.

The power of a brand is not the face of brand endorser rather it’s the business ethics of the company. Patanjali became a quick hit as consumers connected with the deity image of yoga guru Ramdev and his simple style of living. But the connect is not forever.

It started promoting the brands as ‘swadeshi‘ and ended up listing its products on American giant Amazon. It shows the difference between what they say and do. The revival of brand Patanjali seems difficult and is only possible if they run the company professionally.

K. Vaitheeswaran, a serial entrepreneur and author of the book Failing To Succeed suspects there’s something wrong with either the quality of Patanjali’s products or its distribution network.

“Developing and launching FMCG products is not tough. It is also not difficult to get early sales and momentum,” Vaitheeswaran said.

“Maintaining the sales momentum, however, requires a lot. The product quality must be so good that it creates a positive word of mouth leading to a cycle of repeat sales. There should also be enormous discipline in creating a sales process across distributors, stockists, retailers to ensure steady movement of inventory on and off the shelves.

“This is a strong point of the multinational FMCG giants. I suspect that if any one of these things is not maintained, early sales momentum will drop.”

https://theprint.in/india/baba-ramdevs-patanjali-is-in-a-free-fall-it-cant-be-blamed-on-the-slowdown-alone/287917/ via

Unplanned expansion, a poor supply chain, inconsistent product quality and business practices, combined with the slowdown, have badly hurt Patanjali's revenues.

10/08/2019

bounces back to double digit of 13.2% and worth INR 11927 Crs in 2019.

Source:

09/08/2019

Former Myntra-Jabong CEO Ananth Narayanan is learnt to be taking over as the CEO role at Medlife

Medlife was founded by Tushar Kumar, son of Prabhat Narain Singh, one of the founders of Alkem Laboratories.

Medlife, which sells medicines online along with facilitating diagnostic tests and doctor consultation, is currently in talks with Cipla for a funding round which is estimated at $100-150 million.

Ananth Narayanan spent 15 years at McKinsey. Narayanan has been backing startups in his personal capacity with investments in Curefit, scooter rental startup Vogo, education platform Unacademy.

For Medlife, bringing someone like Narayanan will help it go out and raise finance. Earlier this year, Medlife, founded by Tushar Kumar and Prashant Singh in 2014, acquired Bengaluru-based medicine-delivery startup Myra in an all-stock deal, indicating early signs of consolidation in India's crowded e-pharmacy sector.

Medlife, which competes with the likes of 1MG, Netmeds and PharmEasy, said its sales grew to nearly 700 crore in FY19. Medlife is targeting 1,400-1,500 crore in the current fiscal.

According to a recent report by RedSeer Consulting, India's top four e-pharmacies including Medlife, Netmeds, 1MG and PharmEasy contributed 90% to online drug sales. The average order value has gone up to Rs 1,200 with customers ordering on average 10 times per year.

09/08/2019

is in talks to invest in healthcare platform , in what could perhaps be the first investment by a traditional pharmaceutical company in an e-pharmacy. Cipla is looking to invest Rs 150-170 crore in the , which sells medicine online and offers lab tests and .

Talks are in advanced stages as Cipla has been interested in the online sector for a while. Cipla has looked at all the companies in the online space, tracking it closely.

When contacted, Cipla declined to comment on the matter, while Medlife CEO Tushar KumarTushar Kumar denied any such talks with Cipla.

If the deal finally goes through, this could change the dynamics of the online pharmacy market that so far has largely seen early signs of consolidation among online peers. In May, Medlife acquired Bengaluru-based online medicine delivery startup , which specialises in two-hour deliveries. Last year, it acquired startup EClinic24/7, adding chat and video-based doctor consultations.

Medlife is one of the largest players in terms of sales of Rs 1,000-1,200 crore annually, which includes lab and diagnostics segment sales.

23/04/2019

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/many-essential-drugs-priced-much-higher-than-manufacturing-cost-who/articleshow/68917411.cms

Even off patent drugs which are in the market for long and commonly used for diseases like HIV, tuberculosis and malaria are priced very high.

23/04/2019

Base Pharmaceuticals Pvt Ltd
Hiring and Hiring big at Patiala

23/04/2019

https://business.medicaldialogues.in/drugs-registered-on-sugam-portal-to-be-exempted-from-obtaining-licence-for-purpose-of-examination-test-analysis/

The exemption from obtaining a licence for Form 29 is subject to the condition that the information about the manufacturing of approved drugs for examination, test or analysis shall be uploaded on the SUGAM Portal.

23/04/2019

https://health.economictimes.indiatimes.com/news/pharma/new-legal-risks-emerge-for-indian-pharma/68950128

Dr Reddy’s Labs, Aurobindo, Cadila and Glenmark face the highest risk

23/04/2019

https://health.economictimes.indiatimes.com/news/pharma/carlyle-zydus-and-advent-join-race-to-acquire-bharat-serums-and-vaccines-ltd/68983456

They are up against domestic pharma companies Dr Reddy's Labs, Mankind & Goldman Sachs which have also made offers.